When no one owns a resource, we tend to overuse it–winding up with polluted skies, fished-out oceans and battles over access to freshwater. But too much ownership leads to problems too
The pharmaceutical industry is one of the few sectors around that appears to be weathering these difficult times with relative ease.
In recent years, efforts to combat drug-resistant bacteria have focused on the immediate goal of reducing rates of hospital-acquired infections. But now global health officials face an approaching crisis: the number of different antibiotics available to treat such infections when they do occur is dwindling because pharmaceutical companies have neglected to invest in the development of new types of drugs
Pharmaceutical giant Pfizer has agreed to pay a record $2.3 billion settlement to resolve criminal and civil liability for illegally promoting certain pharmaceuticals, the Justice Department announced Wednesday.
It was only a few years ago that an up-and-coming member of the House Democratic leadership pointed to a cozy arrangement in the Republican-written Medicare prescription-drug program as a symptom of everything wrong with Washington. The 2003 bill barred the government from negotiating for lower drug prices for its 43 million Medicare recipients. Instead, that task was delegated to private insurers and their agents, whom Democrats argued and still argue don’t have the muscle to get the steep discounts that a huge government program could.
At least eight people have died from eating tainted peanut products in recent months, and the Food and Drug Administration has absorbed much of the blame. It is the latest in a series of black eyes for the FDA over unsafe foods, dangerous medicines such as Vioxx and allegedly cozy ties with the pharmaceutical industry it regulates